The B4GALT7 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human A-549 lung carcinoma cell line, featuring targeted disruption of the B4GALT7 gene. This gene encodes beta-1,4-galactosyltransferase 7, which initiates glycosaminoglycan chain synthesis. The polyclonal format provides a heterogeneous pool of loss-of-function cells, ideal for studying gene function without clonal biases.
A-549 cells, isolated from human lung adenocarcinoma tissue, display adherent epithelial morphology and are extensively used in respiratory research, toxicology, and cancer biology. Their robust expression of proteoglycans and well-mapped signaling pathways make them a relevant host for investigating glycosylation-dependent processes in lung cancer.
B4GALT7 catalyzes the transfer of galactose from UDP-galactose to the xylose residue of the proteoglycan linker region, a reaction dependent on Mn2+. It operates downstream of xylosyltransferases (XYLT1/2) and upstream of B3GAT3. The enzyme is regulated by SP1, TGF-?? signaling, and NRF2. Its activity is essential for the assembly of heparan sulfate, chondroitin sulfate, and dermatan sulfate chains on core proteoglycans, including syndecans and glypicans. These glycosaminoglycan chains serve as co-receptors for growth factors like FGF2, VEGF, and Wnt morphogens, influencing signaling cascades such as ERK and AKT pathways. Consequently, B4GALT7 knockout disrupts glycosaminoglycan biosynthesis, impairing extracellular matrix organization and growth factor signaling.
In the A-549 background, B4GALT7 disruption provides a model to dissect the contribution of glycosaminoglycans to lung adenocarcinoma cell adhesion, invasion, and mitogenic signaling. Loss of heparan sulfate compromises syndecan- and glypican-mediated growth factor presentation, leading to attenuated responses to FGF2 and altered VEGF/Wnt signaling. This system also enables investigation of disease mechanisms underlying Ehlers-Danlos syndrome and other congenital disorders of glycosylation in a cancer-relevant context.
Researchers can utilize these cells in western blotting for core proteoglycans, immunofluorescence detection of heparan sulfate, HPLC-MS disaccharide profiling, cell adhesion and migration assays, and phospho-ERK/AKT analysis. Additional applications include qPCR quantification of glycosyltransferase expression and functional rescue studies. The polyclonal knockout population is well-suited for population-level analyses, drug screening, and genetic interaction studies. For further technical information, please contact Ascent Research.
